| Date | Title | Description |
| 11.08.2026 | Peptide Synthesis Market Trends: Drug Development and Biopharmaceutical Innovation Driving Growth | The peptide synthesis market is witnessing strong growth as peptides gain increasing importance in pharmaceutical research, therapeutic development, diagnostics, and biotechnology. Peptide synthesis enables the production of customized pept... |
| 09.07.2026 | Syngene FY26 profit falls 20%, revenue rises 3% | - |
| 16.06.2026 | Biocon eyes crown of world’s top insulin supplier amid rush for GLP-1 | Mumbai: Indian drugmaker Biocon Ltd. is aiming to become the world’s top supplier of insulin in the coming years, co-founder Kiran Mazumdar-Shaw said, by capturing growing demand for the critical diabetes drug while Big Pharma shifts its fo... |
| 21.01.2026 | Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035 | BENGALURU, India, Jan. 21, 2026 /PRNewswire/ -- Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced the extension of its long-standing strategic collaboration with Bristol ... |
| 09.11.2025 | Syngene eyes growth tailwinds from global trial wins, biotech funding recovery: CEO | - |
| 14.08.2025 | India's CRDMO Market Attracts Major Investment as Aragen Secures Rs 300 Cr | Avendus Future Leaders Fund III, alongside SBI Life Insurance, recently invested Rs 300 crore in Aragen Life Sciences. This strategic funding highlights robust confidence in India's booming Contract Research, Development, and Manufacturing ... |
| 13.08.2025 | Avendus Fund leads Rs 300 Cr investment in Aragen Life Sciences | Avendus Future Leaders Fund III, the flagship private strategies vehicle of Avendus Group, has led a Rs 300 crore ($36 million) investment in Aragen Life Sciences, one of India’s largest contract research, development, and manufacturing org... |
| 07.08.2025 | BharatPe turns profitable, reports adjusted profit before tax of Rs 6 crore | Synopsis
ET reported on August 1 that the company is expecting to report a profit before interest, taxes, depreciation and amortisation in its fiscal 2025 results, and is eyeing funding of $100 million.
ETtech
Fintech major BharatPe reporte... |
| 23.07.2025 | At ₹87 crore, Syngene posts 61% growth in profit in Q1 | - |
| 10.07.2025 | Syngene, RICH, Biocon Foundation Launch Third Cohort of Women-in-STEM Program Now in its third year, the program is benefitting 40 women students selected after a competitive process that evaluated ac... | Syngene International, in collaboration with the Research and Innovation Circle of Hyderabad (RICH) and Biocon Foundation, has announced the launch of the third cohort of its flagship women-in-STEM scholarship and mentoring program.
Designe... |
| 24.04.2025 | Bulls take breather: Nifty, Sensex snap 7-session winning streak on expiry day, FMCG drags | While large-cap indices declined, broader markets outperformed and pharma stocks provided some cushion.
Bulls took a breather in trade on April 24, leading the benchmark indices Nifty 50 and Sensex to snap a seven-session winning streak, as... |
| 24.04.2025 | Syngene International’s shares slide 13% amid cautious FY26 outlook | - |
| 20.03.2025 | Syngene completes US biologics site acquisition, shares trade flat | Syngene International had informed the exchanges late last night that Syngene USA has completed the acquisition of its first biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC, a subsidiary of Emergent BioSoluti... |
| 15.03.2025 | Indian Pharma's Bold Leap into the U.S. Market: A New Era of Acquisitions | The Indian pharmaceutical industry is on the move. Like a ship navigating through stormy seas, companies are expanding their reach into the U.S. market. This surge in acquisitions is not just a trend; it’s a strategic response to shifting t... |
| 14.03.2025 | Indian pharma ramps up US acquisitions amid regulatory and market shifts | Indian pharmaceutical companies are aggressively expanding their US presence through a wave of acquisitions, likely as a hedge against future uncertainties. Leading players like Sun Pharma, Syngene, Senores, and Zydus have all made strategi... |
| 10.03.2025 | Syngene acquires first US facility from Emergent Manufacturing | Syngene International, the contract research wing of Biocon Group, has acquired its first manufacturing facility in the US from Emergent Manufacturing Operations Baltimore. The pharma player has invested around $50 million, including the co... |
| 28.11.2024 | Syngene International Adopts Genedata Screener as Collaborative Solution for In Vitro Assay Analysis | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Genedata Screener used to ensure standardized assay data and data flow across pa... |
| 23.10.2024 | Syngene International’s CFO Sibaji Biswas resigns | Syngene International Limited’s Executive Director, Chief Financial Officer (CFO), Sibaji Biswas has resigned to pursue other career opportunities. He will be replaced by Deepak Jain effective from December 1.
The company said in its filing... |
| 23.10.2024 | Biocon’s Syngene reports 9% dip in PAT at ₹106 crore in Q2 | Syngene International Ltd, the research arm of Biocon, reported a 9 per cent dip in profit after tax (PAT) at ₹106 crore in Q2 FY25, down from ₹117 crore in the same quarter the previous year.
Operational revenue fell 2 per cent to ₹891 cro... |
| 09.08.2024 | Biocon Net Profit of Up By 550% to INR 660 Crore for Q1FY25 Biocon generated a total revenue of INR 4,567 crore in Q1FY25 and witnessed a net profit of 550 per cent | Biocon reported a total consolidated revenue of INR 4,567 crore for Q1FY25, a 30 per cent year-on-year (YoY) increase from the same period previous year. Other income includes proceeds of INR 1,057 crore on account of the strategic collabor... |
| 25.07.2024 | Syngene Q1 net profit down 19% to ₹75.7 crore | Syngene International Limited, the contract research unit of Biocon, has reported a dip of 19 per cent year-on-year (Y-o-Y) in profit after tax (PAT) from ₹93.4 crore to ₹75.7 crore in the first quarter that ended June 30, 2024.
Also read: ... |
| 21.05.2024 | Expect formulations biz to outpace API biz: Biocon Group CEO Peter Bains | - |
| 25.04.2024 | Syngene Q4 results: Net profit up 6% to Rs 189 cr, revenue declines 8% | - |
| 05.07.2023 | Acquisition. Syngene to acquire Unit 3 biologics manufacturing site for gross value of ₹702 cr | Syngene will acquire a Unit 3 biologics manufacturing facility in Bengaluru from Stelis Biopharma Limited (SBL) on a slump sale basis for a gross value of ₹702 crore.
The companies have entered into a binding term sheet. According to Syngen... |
| 02.12.2021 | Usage of Phase-Appropriate Quality Systems in Drug Development, Upcoming Webinar Hosted by Xtalks | While their process is flexible, they have also established proper controls ensuring they maintain the necessary compliance standards.
TORONTO (PRWEB) December 02, 2021
To overcome the challenges faced during the drug development lifecycle,... |
| 14.10.2021 | A Practical Roadmap for IND-Enabling Safety and Toxicology Studies, Upcoming Webinar Hosted by Xtalks | Preclinical toxicology studies should reliably assess the safety of new drug entities, thus building a multi-faceted understanding of compounds to lay the groundwork for clinical trials and regulatory approval.
TORONTO (PRWEB) October 14, 2... |
| 05.08.2021 | Syngene Announces Senior-Level Appointments | Strengthens leadership in USA
Alex Del Priore appointed as Senior Vice President, Manufacturing Services
Alan Collis appointed as Vice President, Integrated Drug Discovery Services
Syngene International, an integrated research, development,... |
| 20.07.2021 | Technology Transfer: A Systemic Approach to Achieve Manufacturing Process Milestones, Upcoming Webinar Hosted by Xtalks | So far, Syngene has achieved 15 successful technology transfers in the last two and a half years, without any failure or major technical glitches.
TORONTO (PRWEB) July 20, 2021
The current main challenge in technology transfer for both CDMO... |
